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PURPOSE. Fuchs’ endothelial corneal dystrophy (FECD) is a degenerative eye disorder affecting
4% of Americans older than 40. It is the leading indication for corneal endothelial (CE)
transplantation for which there is a global donor shortage. This study aimed to gain further
insight into the pathophysiology of FECD and identify targets for nonsurgical therapy.
METHODS. CE from patients with late-onset FECD was compared with that of normal controls
using microarray expression analysis (n ¼ 4 FECD, n ¼ 4 normal), reverse transcriptase
quantitative PCR (n ¼ 9 FECD, n ¼ 8 normal), and immunohistology (n ¼ 55 FECD, n ¼ 15
normal).
RESULTS. This led to the identification of circulating fibrocytes and their dendritic derivatives in
all examined CE samples with FECD (in all clinical stages of symptomatic FECD and
independent of prior cataract surgery). These cells were not present in normal CE. In this
study we characterize their morphology, protein expression profile, number, and localization
within the CE layer of patients with FECD.
CONCLUSIONS. Circulating fibrocytes and their dendritic derivatives are a new aspect of FECD
that deserves further investigation. Because they are known to cause fibrosis in a variety of
organs, they may play a similar role in FECD and might be a valuable target for nonsurgical
therapy.
Keywords: Fuchs’ endothelial corneal dystrophy, circulating fibrocytes, dendritic cells,
fibrosis, epithelial-mesenchymal transition
Fuchs’ endothelial corneal dystrophy (FECD) is a degenera-tive corneal disorder that is estimated to affect 4% of
Americans older than 40.1 The exact incidence is unknown
because symptomatic FECD is preceded by an asymptomatic
phase that does not always evolve into symptomatic disease.1,2
In the asymptomatic phase (i.e., clinical stage I)2 corneal guttae
develop, which are drop-like excrescences of extracellular
matrix (ECM) on the Descemet membrane (DM). Symptomatic
progression occurs during the course of 2 to 3 decades.3
Although an early-onset form of FECD exists (manifesting in the
2nd to 3rd decade of life), this form is very rare.1 The current
study included only late-onset cases of FECD (manifesting in the
5th to 6th decade of life).3
FECD usually affects both eyes and clinically progresses
from blurred vision to painful erosions and even blindness.1,4
The blurred vision is caused by corneal swelling as a result of a
defect in the inner corneal layer, that is, corneal endothelium
(CE).1,4 CE is derived from the neural crest (not related to
vascular endothelium).5 Normal CE is a monolayer of hexagonal
cells in postmitotic arrest that rest on the DM.6 Normal CE acts
as a selective barrier and active pumping system for water and
nutrients across the avascular cornea, safeguarding corneal
transparency.1,4 In FECD, CE function is impaired as a result of a
critical loss of CE cells (CECs) and thickening of the DM with
the appearance of guttae.1,4
FECD displays a high familial risk and can be inherited in an
autosomal dominant-like way, but most cases are sporadic.4,7
Smoking is a risk factor and women are 2.5 to 3.5 times more
frequently affected than men.1,4,8 Several mutations, sequence
variants, and chromosomal loci have been linked to
FECD,1,4,9,10 but each of those accounts for only a subpopula-
tion of patients. Cellular functions that play a role in FECD
include ECM deposition, oxidative stress, apoptosis, and
epithelial-mesenchymal transition (EMT),1,4,9,11,12 but a unify-
ing theory is lacking.
FECD is the leading indication for transplantation of the CE
in the United States.13 Given the global shortage of donor
corneas and the expected rise in prevalence of FECD with the
aging of the population, this study aimed to gain more insight
into the pathophysiology of FECD to identify targets for
nonsurgical therapies.1,14
iovs.arvojournals.org j ISSN: 1552-5783 670
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/935965/ on 03/30/2017
MATERIALS AND METHODS
Acquisition of Human Samples and Study Approval
Fresh ‘‘CE-DM complexes’’ (CE monolayers with DM) were
prospectively collected from patients with symptomatic late-
onset FECD (clinical stages II to IV)2 during endothelial
keratoplasty (CE transplantation). The diagnosis of FECD was
made by corneal specialists, based on clinical history, split-
lamp biomicroscopic examination (bilateral presence of
central guttae with or without edema), and disease progression
and excluding other intraocular pathologies (such as uveitis or
other inflammatory eye conditions). Patients with previous
intraocular surgery other than cataract surgery were excluded
from this study. Controls originated from donor corneas and
enucleations for uveal melanoma (without corneal extension
or prior radiotherapy). The retrieval of donor corneas was
performed according to the European Eye Bank Association
guidelines, within an average of 6 hours of warm ischemia or
14 hours of cold ischemia. Prior to transplantation and CE-DM
collection, donor corneas were stored by organ culture in Stem
Alpha medium (Stem Alpha, Saint-Genis-l’Argentie`re, France),
Eurobio medium (Eurobio, Les Ulis, France), or minimal
essential medium supplemented with calf serum and antibiot-
ics; dextran was added to reduce swelling prior to transplan-
tation.
This material was either collected in RNAlater (Ambion by
Life Technologies, Carlsbad, CA, USA or Qiagen) for RNA
extraction or mounted on tissue slides, with CE facing up, for
whole-mount staining. Some samples were partitioned and
mounted on multiple slides to enable multiple stains for the
same sample (these samples were counted only once to
calculate the total number of samples for immunohistochem-
istry (IHC) and immunofluorescence (IF) and to calculate
patient characteristics). Slides were air dried, fixed in acetone,
and stored at 208C.
This study included only residual human material and was
approved by the local institutional ethics committee and
biobank of UZ Leuven (Commissie Medische Ethiek UZ KU
Leuven/Onderzoek; study number S55133) in adherence with
the tenets of the Declaration of Helsinki.
RNA Extraction for Microarray Expression
Analysis and Reverse Transcription Quantitative
Real-Time PCR
CE-DM complexes were manually homogenized with a
disposable pestle. RNA extraction was performed with an
RNeasy Micro Kit (Qiagen) without DNase treatment (to
maximize RNA yield).
Microarray Expression Analysis
Eight RNA samples were selected for microarray expression
analysis: four FECD (age 75.5 [4.0], mean [standard deviation]
in years; female:male [F:M] ratio 3:1) and four normal control
samples (age 52.8 [18.8]; F:M ratio 0:4). RNA concentration
and quality was measured using spectrophotometry (Nano-
Drop ND-1000, Thermo Scientific, Waltham, MA, USA). RNA
integrity ranged between 6.70 and 7.90, as measured with a
Bioanalyzer 2100 (Agilent, Santa Clara, CA, USA). For each
sample, 100 ng of total RNA was spiked with bacterial poly-A
RNA positive controls (Affymetrix, Santa Clara, CA, USA) and
used to generate second-cycle cDNA with the Ambion WT
Expression Kit. Samples were fragmented and biotin-labelled
using the Affymetrix WT Terminal Labeling Kit. A mixture of
fragmented biotinylated cDNA and hybridization controls
(Affymetrix) was hybridized on Affymetrix GeneChip Human
Gene 1.0 ST Arrays, followed by staining and washing in a
GeneChip fluidics station 450 (Affymetrix). Chips were
scanned using a GeneChip scanner 3000 (Affymetrix) to assess
the raw probe signal intensities.
MEA was completed in the R programming environment
with Bioconductor packages (http://www.bioconductor.org, in
the public domain). The analysis was based on the robust
multiarray average expression levels of the probe sets with the
package xps (version 1.7.2). Probe sets with ‡1 present
detection call above background were taken into account for
further analysis (27,818 probe sets). The average number of
present calls per sample was 26,342 (91.2%), with a standard
deviation of 416 (1.4%), and comparable average background
and scaling factors across the slides. Differential expression
was assessed via the moderated t statistic.15 To control the false
discovery rate (FDR), multiple testing correction was per-
formed.16
Pathway and function analysis was completed using
Ingenuity Pathway Analysis version 8.5-2803 (IPA; Qiagen,
Redwood City, CA, USA), with all 27,818 probe sets as input.
Of the entries, 19,254 could be mapped to molecules in the
Ingenuity Knowledge Base. Probes with jlog2 (FECD/normal)j
‡ 1 and FDR-corrected P value < 0.05 were selected. Probe
sets referring to the same molecule were resolved by taking the
average of the log-ratio values. This resulted in 617 eligible
molecules for gene networks and 628 for functions, pathways,
and lists.
Reverse Transcription Quantitative Real-Time PCR
(RT-qPCR)
Two Custom RT2 Profiler PCR Arrays (CAPH10409 and
CAPH104010; Qiagen) were designed, comprising 197 genes
of interest based on MEA data: 85 fulfilled the cut-off criteria
jlog2 (FECD/normal)j ‡ 1 and FDR-corrected P value < 0.05;
94 genes were added to complement the pathways of interest,
as identified by IPA. RNA concentration and quality was
measured using spectrophotometry (NanoDrop ND-1000).
Nine unpooled FECD (age 67.8 [8.0]; F:M ratio 5:4) and eight
unpooled normal control samples (age 59.6 [12.3]; F:M ratio
2:6), different from those used for MEA, were analyzed with RT-
qPCR. Five of 9 FECD samples and seven of eight normal
samples contained enough mRNA to be used on both arrays;
the other samples were used on one array each. Per array, 100
ng of total RNA was reverse transcribed to cDNA with the RT2
First Strand Kit (Qiagen). Arrays were run on the 7900 HT Fast
Real-Time PCR System (Applied Biosystems) using RT2 SYBR
Green ROX qPCR Mastermix (Qiagen).
Data analysis was performed through the web portal of
Qiagen (http://qiagen.com/geneglobe, in the public domain).
The software performed comparative threshold cycle calcula-
tions on the uploaded raw threshold cycle (Ct) data.
Normalization was done using the average arithmetic mean
of Ct values from three reference genes (RPL13A, RPL19, and
RPS5) that were stably expressed in FECD and normal control
samples. Ct cut-off was set to 35. Higher Ct values and missing
values were imputed with a Ct value of 35. A 2-sided t statistic
was used (a ¼ 0.05).
Immunostaining on Whole-Mount Specimens
Staining was performed manually or in an automated way with
a BOND-MAX stainer (Leica Microsystems, Wetzlar, Germany)
or a Link 48 (Dako, Glostrup, Denmark) using diaminobenzi-
dine (brown), alkaline phosphatase (red), or amino-ethyl-
carbazole (red) as chromogens. Prior to staining with the
peroxidase substrates (diaminobenzidine and amino-ethylcar-
bazole), endogenous peroxidase activity was blocked with
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Peroxidase Blocking Solution (Dako) for 10 minutes at room
temperature. Pretreatment, dilution, and incubation conditions
(Supplementary Table S1) were optimized on fresh-frozen
positive control specimens that also served as batch controls.
Horseradish peroxidase-labelled EnVision FLEX (Dako) or Bond
Polymer Refine Red Detection (Leica) were used as a
secondary antibody for 30 minutes. Sections were counter-
stained with hematoxylin and mounted.
IF double staining consisted of combinations of antisera
from different hosts (mouse and rabbit) and goat-anti-mouse or
goat-anti-rabbit antibodies labelled with Alexa Fluor 488 or
Alexa Fluor 568 (Invitrogen by Life Technologies) as secondary
antibodies. Dye swaps ensured the specificity of staining. Slides
were counterstained with DAPI (Invitrogen) and mounted with
glycerol gelatin or ProLong Gold antifade reagent (Life
Technologies).
In total, 55 CE-DM samples from patients with FECD (age
70.1 [8.14]; F:M ratio 36:19) and 15 normal control samples
(age 60.1 [15.8]; F:M ratio 10:5) were tested with IHC and IF.
Image Acquisition and Processing
Brightfield images were acquired with a NanoZoomer 2.0-RS
(Hamamatsu, Hamamatsu City, Japan), Ultra Fast Scanner 1.6
IVD (Philips, Amsterdam, Netherlands), or DM LB microscope
with DC300 camera and IM50 software (Leica). Sample
surfaces were calculated with an NDP viewer 2.2.10 (Hama-
matsu), IntelliSite Pathology Solution IMS 2.3 (Philips), or Fiji17
(ImageJ 1.48c; ImageJ, Madison, WI, USA), respectively. Images
acquired with the Leica microscope were white balanced,
matched for brightness, and corrected with a flatfield
background image using EZ Image Prep from ChromaCal
Image Calibration 2.5.1 (Datacolor, Lawrenceville, NJ, USA).
IF images were acquired in z-stack using the Leica SP8x
confocal microscope. Fiji was used to improve contrast, merge
color channels, project the maximum intensity in two
dimension, and define scale bars.17
The number of immunoreactive cells was counted manually
for each marker on the entire sample surface using VersaCount
1.02.18 Dot plots with 95% confidence intervals were created
with GraphPad Prism 6.01 (GraphPad, San Diego, CA, USA).
The average number of cells expressing a specific marker was
weighted per mm2 to account for differences in sample surface
and for partitioned samples. Cells were manually mapped on
whole-slide images and summarized schematically (see Fig. 6).
Double-stained samples were counted separately for each of
the applied antisera.
RESULTS
Genes Related to Inflammation, Antigen
Presentation, and Dendritic Cell Maturation Are
Significantly Differentially Expressed in FECD
MEA was used to compare the corneal endothelial tran-
scriptome of four FECD and four normal control samples. For
this, RNA was extracted from CE-DM complexes, which
contain only CECs, allowing a reliable comparison of the gene
expression profiles. Unsupervised computational analysis
clearly segregated FECD samples from normal donor samples
(Fig. 1a), indicating a marked difference in the gene expression
between both groups. This experiment revealed 954 signifi-
cantly differentially expressed probe sets (487 probe sets were
‡ twofold upregulated and 467 were ‡ twofold downregulat-
ed in FECD with an FDR-corrected P < 0.05).
IPA analysis of the MEA data indicated a role for functions
that are currently not linked to the pathophysiology of FECD,
such as inflammatory response, inflammatory disease, and
antigen presentation (Supplementary Fig. S1, Supplementary
Table S2). Notably, one of the top gene networks was centered
on upregulation of major histocompatibility complex (MHC)
class II molecules related to antigen presentation (Fig. 2), with
major histocompatibility complex, class II, DR alpha (HLA-
DRA) being the second most upregulated gene in FECD (fold
regulation¼ 73.95, P < 0.001). The most significant canonical
pathways included dendritic cell maturation; role of macro-
phages, fibroblasts, and endothelial cells in rheumatoid
arthritis; and hepatic fibrosis/hepatic stellate cell activation
(Supplementary Fig. S1, Supplementary Table S2). Note that
hepatic stellate cells are a subset of myofibroblasts that play a
role in fibrotic liver disorders.19 Gene set enrichment analysis
(Supplementary Methods) confirmed the significant upregu-
lation of genes related to dendritic cell maturation (Fig. 1d,
Supplementary Fig. S1).20
In addition, MEA revealed biological functions (P < 0.001)
that are consistent with previously reported processes in FECD
(Supplementary Table S2), supporting the external validity of
this experiment. These functions included connective tissue
development and function (FECD is characterized by ECM
deposition),1 posttranslational modification and free radical
scavenging (unfolded protein stress and oxidative stress play a
role in FECD),1,9 cell cycle and cell death (senescence and
aberrant apoptosis of CECs have been reported in FECD),1,4
and nervous system development and function (CE originates
from the neural crest).5
RT-qPCR Provides Technical and Biological
Validation of the MEA Results
We used RT-qPCR to validate the MEA results on a new and
larger set of unpooled samples (n¼ 9 FECD, n¼ 8 normal). For
this, we selected 179 genes of interest based on their MEA
expression values and role in MHC class II type antigen
presentation, dendritic cell maturation, inflammation, chemo-
taxis, growth factor activity, EMT, and ECM production.
The RT-qPCR results correlated strongly with the MEA
results (R2 ¼ 0.82, P < 0.0001, Fig. 1c), and unsupervised
clustering could again segregate FECD from normal samples
(Fig. 1b).
MEA and RT-qPCR data have been deposited in NCBI’s Gene
Expression Omnibus21 and are accessible through the Gene
Expression Omnibus Series accession number GSE75676
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc¼
GSE75676, in the public domain).
Whole-Mount Staining of CE-DM Complexes
Identifies the Presence of Cells With Dendritic and
Monocyte-Like Phenotype in FECD
As HLA-DRA was one of the top upregulated genes in FECD,
according to MEA (fold regulation¼ 73.95, P < 0.001), which
was confirmed by RT-qPCR (fold regulation ¼ 169.07, P ¼
0.009), IHC was performed for the HLA-DR a chain (HLA-DRA)
on CE-DM whole mounts. Surprisingly, this revealed the
presence of HLA-DRAþ cells with dendritic morphology in all
of the examined FECD specimens (Fig. 3b), but in none of the
controls (Fig. 3a). Another marker related to antigen presen-
tation, namely CD45 (marker of hematopoietic cells),22
unveiled two subsets of cells, that is, cells with dendritic
morphology and moderate CD45 expression, and a smaller
subset of monocyte-like cells with bean-shaped nuclei, strong
CD45 expression, and lacking dendritic processes (Fig. 3c). IF
double staining for CD45 and a smooth muscle actin (aSMA;
mesenchymal marker, and marker of EMT; Fig. 4c), HLA-DRA
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and aSMA (Fig. 4d), as well as HLA-DRA and CD45 (Fig. 5a)
showed coexpression of each of these marker pairs within cells
with dendritic morphology. In addition, aSMA diffusely stained
the CE layer in FECD (Fig. 3f).
Notably, IHC staining for HLA-DRA and CD45 on transversal
sections of full-thickness corneas was not suited to demon-
strate the presence of cells with dendritic or monocyte-like
morphology in FECD. This was a result of sampling bias (for
the monocyte-like subset) and the long and slender dendritic
processes with scant cytoplasm that only occasionally present-
ed as small dots and were easily overlooked (for the dendritic
subset). Transversal staining for aSMA, on the other hand,
confirmed a general upregulation of this protein in the CE layer
of patients with FECD.
Immunofluorescent Double Staining of CE-DM
Complexes Identifies Circulating Fibrocytes in
FECD
Next, we aimed to identify the origin and nature of the
dendritic and monocyte-like subsets of cells in FECD: either
they are derived from CECs (through the process of EMT) or
they are a different cell type that has thus far not been
described in FECD. Although the expression of aSMA is
compatible with EMT, the expression of CD45 (a specific
marker for cells of hematopoietic origin that cannot be
obtained by cells of another lineage, not even during the
process of EMT)22–24 pleads strongly against CE origin.
Furthermore, these observed bean-shaped nuclei are typical
for cells from the monocyte-lineage.
IF double staining for CD34 and collagen I (Fig. 4a) and for
CD45 and collagen I (Fig. 4b) revealed coexpression of both
marker pairs within cells with monocyte-like morphology. This
coexpression profile is the specific signature of circulating
fibrocytes. Circulating fibrocytes are bone marrow–derived
cells that coexpress hematopoietic markers (such as CD34 and
CD45) and mesenchymal markers (such as collagen I)25 and
that are derived from the monocyte/macrophage lineage (with
characteristic bean-shaped nuclei). They can differentiate into
a variety of phenotypes related to their mixed hematopoietic
character (cytokine producing or antigen presenting [HLA-
DRAþ]) and mesenchymal character (ECM producing
[aSMAþ]).25 During this differentiation they can lose surface
markers such as CD34 and CD45.26,27 In our study, cells with
dendritic morphology indeed displayed less CD45 and CD34
FIGURE 1. Unsupervised computational analysis of MEA and RT-qPCR data segregates FECD from normal control samples. (a) The heatmap and
cluster analysis (top) of MEA data segregated FECD (8261, 8263, 8265, and 8267) from normal control samples (8264, 8262, 8266, and 8268). Red
indicates similarity between samples. Green indicates dissimilarity between samples. The principal component analysis (bottom) segregated FECD
from normal control samples, with FECD samples clustering together for both components. (b) The heatmap and cluster analysis of RT-qPCR data
(CAPH10409 array on the left, CAPH10410 array on the right) segregated FECD from normal control samples (Nrl). Rows correspond to genes,
columns correspond to samples. (c) The scatterplot with linear regression equation, goodness of fit (R2), P value and number of genes (n), indicates
a strong correlation between RT-qPCR and MEA results. (d) The gene set enrichment analysis (GSEA) of preranked MEA data illustrates the
significant upregulation (peak at the beginning of the enrichment profile, positive normalized enrichment score, and P < 0.05) for dendritic cell
maturation, a canonical pathway identified by IPA analysis (Supplementary Fig. S1). Pos corr: upregulated in FECD versus normal (red). Neg corr:
downregulated in FECD versus normal (blue).
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and more HLA-DRA and aSMA (myofibroblast marker; Figs. 3c,
4c, 5a–e, 6a), suggesting a more differentiated stage.
Morphology, Expression Profile, Number, and
Localization of Circulating Fibrocytes/Dendritic
Derivatives in FECD
To characterize the circulating fibrocyte phenotype in FECD,
we applied a set of 18 markers on CE-DM whole mounts from
55 patients with FECD (clinical stages II to IV)2 and 15 normal
controls using either IHC (one marker per slide) or IF double
staining (two markers per slide; Figs. 3–6). From the 55 FECD
samples, 48 were used to test markers of circulating fibrocytes.
Four of these 48 samples originated from phakic eyes (two
male and two female patients).
These markers included antibodies to CD11b (marker for
precursors of circulating fibrocytes); CCR5, CXCR1, CXCR2,
and CXCR4 (chemokine C-C and C-X-C motif receptors
involved in recruitment of circulating fibrocytes) and matrix
metallopeptidase 9 (MMP9; which is used by circulating
fibrocytes to enter the target tissue). Staining for fibronectin
(n¼ 1) and vimentin (n¼ 1), two other markers of circulating
fibrocytes, proved not useful as both markers also stained CECs
(Supplementary Fig. S2). Indeed, fibronectin is overexpressed
in CECs with FECD,28 and vimentin is a marker of normal
CECs.29 Furthermore, glial fibrillary acidic protein (GFAP; a
marker of hepatic myofibroblasts or stellate cells)30 was
included because of the canonical pathway hepatic stellate
cell activation that was identified by MEA. In addition,
lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1)
was included because it was one of the top 10 significantly
upregulated genes in FECD when compared with controls
according to MEA (fold regulation ¼ 31.68, P ¼ 0.003) and
confirmed by RT-qPCR (fold regulation ¼ 39.87, P ¼ 0.046).
Because LYVE1 can be expressed by macrophages,31 we
wanted to check whether it was also expressed by circulating
fibrocytes (or derivatives) in FECD. Finally, we included
antibodies directed to CD1a (marker for dendritic Langerhans
cells in the corneal epithelium, n¼3)32 and T cell markers CD4
(n ¼ 2) and CD8 (n ¼ 1), for which no immunoreactivity was
observed in FECD specimens.
Circulating fibrocytes/dendritic derivatives were present in
all of the 48 tested FECD samples. No difference in number of
circulating fibrocytes/dendritic derivatives was observed in
phakic versus pseudophakic eyes with FECD. None of the
normal controls contained such cells. Sample sizes per
antiserum are given in Figure 6b for FECD. For normal
controls, the sample sizes were CD45, n ¼ 10; aSMA, n ¼ 9;
HLA-DRA, n¼ 7; collagen I, n¼ 2; CD34, n¼ 1; CD11b, n¼ 1;
CCR5, n ¼ 1; and LYVE1, n ¼ 1.
Figure 6 summarizes the protein expression profile per cell
morphology and per localization within the CE layer and gives
the average number of immunoreactive cells per mm2 of CE for
each of the markers. On pure morphology, we observed a
subset of cells with dendritic morphology and elongated nuclei
and a smaller subset of monocyte-like cells with bean-shaped
nuclei lacking dendritic processes. There were also cells of
intermediate phenotype, with bean-shaped nuclei and wider
cytoplasm, but without clear dendritic processes, suggesting a
continuum between both subsets of cells. With respect to
protein expression profile, the markers CD45, CD34, CD11b,
collagen I, CCR5, CXCR2, and MMP9 were most prominent in
FIGURE 2. Gene network comprising MHC class II molecules is significantly upregulated in FECD. This IPA gene network, based on MEA results, is
composed of the functions antigen presentation, inflammatory response, and cell-to-cell signaling and interaction (P < 0.001; Supplementary Fig.
S1). It shows significant upregulation of HLA-DRA (arrow) and other MHC class II molecules. Red: ‡ 2-fold upregulated (FDR corrected P < 0.05).
Green: ‡ 2-fold downregulated (FDR corrected P < 0.05). Gray: present as input, but not meeting cut-off criteria for red and green. The color
intensity correlates with the degree of gene expression change. Log2 fold-change values and FDR-corrected P values are below each molecule.
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the monocyte-like subset, whereas HLA-DRA, GFAP, CXCR4,
and CXCR1 were most prominent in the dendritic subset of
cells. LYVE1 was expressed by both subsets, again suggesting a
common origin between the cells with monocyte-like and
dendritic morphology. With respect to localization, the
monocyte-like subset was mostly observed in the peripheral
zone of the CE layer, whereas the dendritic subset was mostly
observed in the center, and cells of intermediate phenotype
were concentrated at the interface between the central
confluency of guttae and the peripheral remaining CECs.
HLA-DRA was the most prevalent marker, with a weighted
average of 17.60 cells per mm2 of CE (Fig. 6b). Thus, on an
average whole mount of 42 mm2 (7–8 mm in diameter), more
than 700 HLA-DRAþ cells were present. Not a single FECD
sample (n ¼ 11) lacked HLA-DRAþ cells, and not a single
control sample (n ¼ 7) contained HLA-DRAþ cells.
DISCUSSION
MEA with IPA analysis (n ¼ 4 FECD, n ¼ 4 normal) was
validated on a larger independent set of samples with RT-qPCR
(n¼ 9 FECD, n¼ 8 normal) and led to the immunohistological
identification of circulating fibrocytes and dendritic derivatives
in the CE layer patients with FECD (n ¼ 48 FECD, n ¼ 15
normal). The coexpression of CD34 and CD45 respectively
with collagen I proved their circulating fibrocyte identity,25 a
cell type that causes fibrosis in a variety or organs throughout
the body25,33 but that has not previously been described in
FECD. Circulating fibrocytes/dendritic derivatives were pre-
sent in all examined FECD samples (ranging from clinical
stages II to IV),2 irrespective of prior cataract surgery (which is
usually performed prior to endothelial keratoplasty).
Circulating fibrocytes are considered to be derived from the
monocyte/macrophage lineage (with characteristic bean-
shaped nuclei) because they express monocyte surface
markers such as CD11b.26 They should not be confused with
bone marrow–derived mesenchymal stem cells (which have
been reported to improve corneal recovery via anti-inflamma-
tory mechanisms), which by definition do not express
hematopoietic markers such as CD45, CD34, and CD11b or
HLA-DR.34–37 Circulating fibrocytes are recruited from the
blood to peripheral sites of injury via chemokine ligand/
chemokine receptor axes, such as chemokine C-X-C motif
ligand 12 and receptor 4 (CXCL12/CXCR4).25,33 Upon arrival,
they penetrate the site of injury and can differentiate into a
variety of phenotypes related to their mixed hematopoietic
character (cytokine producing or antigen presenting) and
mesenchymal character (ECM producing).25 They can enhance
physiologic wound healing or cause pathologic fibrosis.27
It is tempting to think that the observed cells with dendritic
morphology are merely CECs with degenerative changes or
CECs that have become myofibroblast-like through the process
of EMT.38 However, the expression of CD45 (a cell-lineage
marker of bone marrow–derived hematopoietic cells that
cannot be acquired by nonhematopoietic cells, not even
during EMT),22–24 strongly pleads against this hypothesis.
Furthermore, the bean-shaped nuclei are characteristic of cells
from the monocyte lineage, as are circulating fibrocytes.
Nevertheless, our data also support the process of EMT in
FECD, consistent with current literature (Supplementary Table
S2). We did not observe an upregulation of the EMT-inducing
FIGURE 3. Immunohistochemistry on CE-DM complexes reveals cells with dendritic morphology in FECD. (a-b) HLA-DRA (brown) showed cells
with dendritic processes that cluster around guttae, as if embracing them, in CE-DM complexes with FECD. No such cells were present in normal CE
samples. (c) CD45 (brown) moderately stained cells with dendritic morphology and strongly stained a smaller subset of monocyte-like cells
(rounded with bean-shaped nuclei) in CE-DM complexes with FECD. (d, e, g–n) Cells with dendritic/monocyte-like morphology also expressed
collagen I (red), CD34 (red), GFAP (brown), LYVE1 (red), CCR5 (red), CD11b (red), CXCR4 (red), CXCR2 (red), CXCR1 (red), and MMP9 (red). (f)
Alpha-SMA (brown), strongly stained cells with dendritic morphology and moderately stained CECs in CE-DM complexes with FECD. (i) The image
for CCR5 shows incidental aggregation of monocyte-like cells in a CE-DM specimen with FECD.
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genes ZEB1 and SNAI1, as reported by Okumura et al.,39 who
studied the EMT profile in immortalized CECs from late-onset
FECD, but we did observe a significant upregulation of ZEB2 in
FECD versus normal as reported earlier in a conference poster
of the same group (Ho L, et al. IOVS 2013;54:ARVO E-Abstract
1680). Differences in these results might be a result of the
difference between in vivo and in vitro (without circulating
fibrocytes) gene expression and to the use of GAPDH as a
reference gene for normalization (as discussed later). In
contrast to Hidayat and Cockerham38 but in line with the role
of EMT in FECD,11 we observed diffuse aSMA expression in the
CE layer of patients with FECD (Fig. 4d) using two different
antisera (Supplementary Table S1) with proper internal and
external controls and consistent with the upregulation of
ACTA2 at the gene expression level (fold regulation¼ 3.69, P¼
0.025, according to RT-qPCR).
Rather than being mutually exclusive, our data suggest that
both processes (EMT and circulating fibrocytes) play a role in
FECD. Notably, EMT and circulating fibrocytes are frequently
reported to contribute simultaneously to tissue fibrosis,
whereby EMT is suggested to occur in later stages (contribut-
ing to the irreversible progression of fibrosis) and circulating
fibrocytes would be present in earlier stages.40 Further study of
the interplay of both processes would certainly be of interest
to elucidate the pathogenesis of FECD.
When comparing our gene expression results with existing
literature (Supplementary Table S2), our data confirm the
significant upregulation of extracellular matrix genes agrin,
collagens (COL1A1, COL4A3, COL4A4, COL4A5, COL4A6,
FIGURE 4. Coexpression of CD34 or CD45 with collagen I identifies circulating fibrocytes in FECD. (a, b) IF double stains revealed CD34þ/collagen
Iþ (a) and CD45þ/collagen Iþ (b) cells with bean-shaped nuclei, corresponding to circulating fibrocytes in CE of patients with FECD. Samples (a) and
(d) originated from phakic eyes from two different patients with FECD, indicating that the presence of cells with monocyte-like (a) and dendritic
morphology (d) is not secondary to cataract surgery. A close-up of a cell with circulating fibrocyte signature (white rectangle in merged pannel [a])
is given at the bottom of the figure. Note the concentric deposition of collagen I fibers around guttae (black spots) in (a) and (b). (c, d) Dendritic
myofibroblast-like cells (CD45þ/aSMAþ/HLA-DRAþ) are present in FECD and surround guttae. Occasionally, monocyte-like CD45þ cells (* in [c]) are
close to cells with dendritic morphology. (d) Alpha-SMA is expressed by cells with dendritic morphology and CECs. (e) No circulating fibrocytes or
cells with dendritic morphology were observed in normal CE. Each column (a–e) represents one sample, with the merged image at the top, and the
composing channels underneath. Yellow indicates coexpression of green and red fluorescently labeled antigens.
Fibrocytes in Fuchs’ Endothelial Corneal Dystrophy IOVS j January 2017 j Vol. 58 j No. 1 j 676
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/935965/ on 03/30/2017
COL5A1, COL6A2), and fibronectin, and the significant
downregulation of ribonuclease DICER1 (involved in miRNA
biogenesis) in FECD versus normal, as reported in litera-
ture.39,41–43 In contrast with existing literature,41,44,45 we found
a significant downregulation of clusterin (CLU), integrins
ITGA3 and ITGB3, MMPs (MMP10 and MMP14), transforming
growth factor beta induced and tissue inhibitor of metal-
loproteinase TIMP1 in FECD versus normal. The upregulation
of extracellular matrix molecules (agrin, collagens, and
fibronectin) and the downregulation of matrix-degrading
molecules (MMPs, which notably degrade agrin) are consistent
with the thickening of the DM in FECD. Furthermore, agrin is a
critical signal for hematopoietic niches,46 and its upregulation
might be related to the presence of circulating fibrocytes in
FECD. The downregulation of integrins (cell adhesion mole-
cules) and CLU (prosurvival factor) is compatible, respectively,
with dysfunctioning and apoptosis of CE in FECD. With respect
to Du et al.,47 who studied differential splicing events in FECD
versus normal, we cannot directly compare our results because
we studied gene expression irrespective of splicing variants.
However, our data show a significant upregulation of EMT-
related genes CSNK1G3 and PPFIBP1, and no differential
expression of splicing regulators MBNL1 and MBNL2. With
respect to oxidative stress genes, our data confirm the
significant downregulation of superoxide dismutase SOD2
and heme oxygenase HMOX1, as reported by Jurkunas et al.48
In addition, we observed a significant downregulation of SOD3
and a significant upregulation of NADPH oxidase activator
NCF2 in FECD versus normal. With respect to senescence
genes, our data confirm the significant upregulation of
ARHGAP18, CCND1, CDK6, CDKN2A, CDKN2B, IGF1,
IGFBP5, IGFBP7, IRF5, NOX4, and PIK3CG in FECD versus
normal, as reported by Matthaei et al.42 However, aldehyde
dehydrogenase ALDH1A3, which was found to be significantly
upregulated in their study,42 was significantly downregulated in
our data, together with dehydrogenases AKR1C2 and ALD-
H3A1, which were also reported to be downregulated in a serial
analysis of gene expression experiment by Gottsch et al.49
Several other genes that were upregulated according to a serial
analysis of gene expression (apolipoprotein D, metallothionein
MT2A, and serum amyloid genes SAA1 and SAA2)49 were
significantly downregulated in our data; and the reverse was
true for activator protein 1 transcription factor subunit FOSB
and ion transporter SLC4A11. These differences in results could
be a result of differences in FECD stages, that is, the patients
examined with a serial analysis of gene expression were derived
from penetrating keratoplasty surgery, whereas our samples
were derived from endothelial keratoplasty (penetrating
keratoplasty is usually performed in later stages than endothe-
lial keratoplasty). Furthermore, others did not find a significant
difference in gene expression for SLC4A11 between FECD and
normal,50 and they argued that expression levels of ion
transporters could be increased in the early stages of FECD.
Apart from FOSB, another activator protein 1 transcription
factor subunit, namely JUN, was also significantly upregulated
in our data, consistent with the current literature.50,51 With
respect to unfolded protein response, our data confirm a
significant downregulation of prefoldin subunit 5, as reported
by Jalimarada et al.50 As a last remark, differences in gene
expression levels between studies can also be a result of the use
of different reference genes for normalization. GAPDH, a
frequently used reference gene,39,41 is unstably expressed in
FECD versus normal (significantly upregulated in our study and
significantly downregulated in other studies48,49) and is
therefore not the best reference gene to study gene expression
in FECD.52 We have selected RPL13A, RPL19 and RPS5 as
reference genes (over GAPDH, ACTB and HPRT1) because of
their stable expression in FECD and normal. RPL13A was also
used by others48,50 because of its small difference in expression
between FECD and control groups.
A limitation to this study is that the samples used for MEA
and RT-qPCR experiments were not matched for age and sex.
However, despite this limitation, the MEA and RT-qPCR results
led to the identification of circulating fibrocytes and dendritic
derivatives in FECD using immunohistology on whole-mount
samples that were matched for age and sex within the
constraints of sample availability (FECD exhibits a female
predominance and late onset,1,4 whereas donor corneas
FIGURE 5. Immunofluorescent coexpression of circulating fibrocyte markers in CE of patients with FECD. Expression of CD45 is observed in
monocyte-like cells, coexpressing CCR5 (c), CD34 (d), CD11b (e), and collagen I (Fig. 4b) and in cells with dendritic morphology, coexpressing
HLA-DRA (a) and aSMA (Fig. 4c). Coexpression of CD45 and LYVE1 (b) was seen in cells of both morphologies. This suggests that both
morphological subsets represent different differentiation stages of circulating fibrocytes. Sample (c) originates from a phakic eye with FECD,
indicating that the presence of (CD45þ/CCR5þ) cells with monocyte-like morphology in FECD is not secondary to cataract surgery. (c, f, g) The
expression of chemokine C-C motif 5 (CCR5) suggests that this receptor might play a role in recruitment of circulating fibrocytes to the CE layer in
FECD. (h) Coexpression of HLA-DRA and GFAP was observed in cells with dendritic and intermediate morphology.
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overrepresent younger and male individuals). This finding was
novel and consistent.
The fact that these cells have not been described previously
despite advanced techniques such as confocal laser scanning
microscopy can be explained by their relatively low numbers
and their morphology. Circulating fibrocytes are typically
described as spindle shaped, compatible with the morphology
of cells in our samples with intermediate and dendritic
morphology, when these would be cross-sectioned. Full-
thickness cross-sections were not suited to detect cells with
dendritic morphology. Also, on CE-DM whole mounts they
could only be detected using specific markers for circulating
fibrocytes. Sampling problems also arise because only an
estimated 700 HLA-DRAþ cells with dendritic morphology
(1.4% of cells in a layer containing 50,400 remaining CECs at
1200 cells/mm2)3 and <300 collagen Iþ cells with monocyte-
FIGURE 6. Protein expression profile, number, and localization of cells with monocyte-like or dendritic morphology in FECD. (a) Protein expression
profiles per cell morphology. Cells ranged from small and round with bean-shaped nucleus (blue, monocyte-like morphology) to larger, plump cells
with abundant cytoplasm and a similar nucleus (green, intermediate morphology), to cells with long dendritic processes and slender elongated
nucleus (yellow, dendritic morphology). Antibodies to CD45, CCR5, collagen I, CD11b, CD34, CXCR2, and MMP9 marked the cells with monocyte-
like morphology, whereas staining for HLA-DRA, GFAP, CXCR4, and CXCR1 marked the cells with dendritic morphology. LYVE1 was present in both
morphological subsets of cells. (b) Number of cells expressing a protein of interest (irrespective of cell morphology) per mm2 of CE in FECD. HLA-
DRA was the most prominent and frequently expressed marker for cells with dendritic morphology, with a weighted average of 17.60 cells/mm2.
Cells expressing HLA-DRA, CD45, CD34, collagen I, aSMA, LYVE1, CD11b, and CXCR4 were present in every tested specimen (n¼ 3–12), whereas
variable expression was seen for MMP9 (positive in 2/4 specimens), GFAP (positive in 4/5 specimens), CCR5 (positive in 4/5 specimens), CXCR2
(positive in 2/3 specimens), and CXCR1 (positive in 2/3 specimens). Error bars: mean with 95% confidence interval. n: sample size. (c) Localization
of cells with different morphologies and localization of markers (irrespective of morphology) within the CE layer of patients with FECD. In the
transition zone between the central confluency of guttae and the peripheral remaining CECs, cells with intermediate morphology were most
prominent, coinciding with the expression of CD45, CCR5, CD34, collagen I, and MMP9. In the central zone, cells with dendritic morphology
prevailed, coinciding with the expression of HLA-DRA, GFAP, CD11b, and CXCR4. In the peripheral zone, cells with monocyte-like morphology
prevailed, coinciding with the expression of LYVE1, CXCR2, and CXCR1. This figure is complementary, but not identical to (a), as illustrated by the
fact that CXCR1 immunoreactivity was mostly observed in the peripheral zone (c), in cells with dendritic morphology (a). CD11b was mostly
observed in the central zone (c) in cells with monocyte-like morphology (a). Alpha-SMA, fibronectin, and vimentin were not included in this figure
because they were also expressed by CECs.
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like morphology (<0.6% of the total cell number) are present
in an average CE-DM specimen of 42 mm2. Furthermore, these
cells cover a broad spectrum of morphologies and marker
combinations, depending on their differentiation state (from
cells with monocyte-like morphology to myofibroblast-like
cells with dendritic morphology), similar to what has been
reported in other fibrosing disorders that involve circulating
fibrocytes.40 These small numbers and diverse phenotypes
would also make it difficult to isolate them from the CE layer
for in vitro studies on their recruitment and exact function in
FECD. Alternatively, circulating fibrocytes could be isolated
from the peripheral blood, similar to what has been done for
other fibrosing disorders.53
With respect to the recruitment of circulating fibrocytes
toward the CE layer in FECD, our mRNA data suggest a role for
chemokine receptors CCR5 (RT-qPCR fold regulation ¼ 10,84,
P¼ 0.019; Figs. 3i, 5c, 5f, 5g, 6), CCR1 (MEA fold regulation¼
3.62, P ¼ 0.036; RT-qPCR fold regulation ¼ 10.05, P ¼ 0.042),
and CX3CR1 (MEA fold regulation¼ 10.32, P¼ 0.003; RT-qPCR
fold regulation¼ 4.92, P¼ 0.017). The differential localization
of cells with different morphology in the CE layer of patients
with FECD (Fig. 6c) suggests that circulating fibrocytes enter
the CE layer peripherally, where we observed the monocyte-
like subset of cells (with rounded contours, consistent with a
recent exit from the circulation), and differentiate into larger
dendritic myofibroblast-like cells toward the center. Therefore,
we speculate that circulating fibrocytes might enter the
anterior eye chamber by extravasation from blood vessels in
the iris-ciliary body, as is common during intraocular inflam-
mation,54 or via the trabecular meshwork, where rare CD45þ
dendritic cells coexpressing monocyte markers have been
reported.55 Although FECD is not accompanied by overt ocular
inflammation, a process of para-inflammation might be active,
similar to other age-associated degenerative diseases of the
immunoprivileged eye (such as adult macular degeneration,
glaucoma, and diabetic retinopathy), which might allow
circulating fibrocytes to enter the anterior chamber.56 Further
research is needed to study the recruitment of circulating
fibrocytes to the CE layer in FECD.
Based on this observational study, we cannot conclude on
the exact function of circulating fibrocytes/dendritic deriva-
tives in FECD. However, these cells are known to cause organ
fibrosis in a variety of disorders, including autoimmune
diseases, such as scleroderma, and chronic inflammatory
disorders that are not classically thought of as autoimmune,
such as idiopathic pulmonary fibrosis, renal fibrosis, liver
fibrosis, and proliferative retinopathy.25,33,53 Similarly, circulat-
ing fibrocytes might contribute to the deposition of ECM that is
characteristic for FECD. If so, they might be a valuable novel
target for the development of nonsurgical therapy. Moreover,
patients with FECD might benefit from therapies that are being
developed for organ fibrosis,57,58 such as CCR1 antagonists
(inhibit circulating fibrocyte trafficking),40 angiotensin II type
1 receptor inhibitors (inhibit fibrogenesis),40 and injections of
serum amyloid P (inhibit fibrocyte differentiation).59 Notably,
ROCK-inhibitors, which are currently tested to treat edematous
corneas,60 might also act on the activity of circulating
fibrocytes via the TGFb1 pathway, as TGFb1 is not only an
inducer of EMT40 but also an inducer of differentiation of
circulating fibrocytes into (myo)fibroblast-like cells.33
Another question that is raised by these data is whether
circulating fibrocytes/dendritic derivatives play a primary or
secondary role in FECD. In this noninterventional study, we
only had access to specimens from symptomatic cases of FECD
(clinical stages II to IV),2 which were collected as residual
human explant material from therapeutic endothelial kerato-
plasty. We detected circulating fibrocytes/dendritic derivatives
in all symptomatic stages of FECD, but we cannot conclude on
their presence in (asymptomatic) stage I of FECD, which would
require an interventional study approach. In a future study we
will use RNA-sequencing and IHC to compare corneas with
FECD to normal and to a third group of edematous corneas
without FECD (such as pseudophakic bullous keratopathy and
endothelial graft failure). This will shed light on the specificity
of circulating fibrocytes in the pathogenesis of FECD. However,
even if the recruitment of these cells would be a common
secondary reaction in CE disorders, they might still qualify as
drug targets to halt disease progression (hypothetically even in
a variety of CE disorders), and their presence refutes the
former dogma that no inflammatory cells are present within
the CE layer of patients with FECD.4 Further study would then
be required to characterize their recruitment, differentiation,
and function in different CE disorders.
In conclusion, circulating fibrocytes and their dendritic
derivatives are a novel and consistent aspect of symptomatic
FECD. Their presence should be taken into account in all
future studies that investigate the CE layer of patients with
FECD. Their recruitment, differentiation, and function in FECD
deserve further investigation because these insights might
present new therapeutic avenues for patients with FECD.
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